BHLHE40 and neoplasm: In addition, treatment with a CD40 agonist antibody preferentially activated the Ccl22+ cDC population and increased Bhlhe40+ T helper 1 (Th1)-like cells and CD8+ memory T cells. The previous studies found that the BHLHE40 + Th1-like cell population is significantly enriched in tumor samples from CRC patients with high microsatellite instability (MSI), who respond to ICB [164, 165].